Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fusidic acid - Aceragen

Drug Profile

Fusidic acid - Aceragen

Alternative Names: ACG-701; ARV-1801; ARV-1907; CEM-102; Sodium fusidate; SQ-16603; Taksta

Latest Information Update: 26 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cempra Pharmaceuticals
  • Developer Aceragen; Arrevus; Cempra Pharmaceuticals
  • Class Anti-infectives; Antibacterials; Cholestadienes; Sterols
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections; Bone and joint infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis-associated respiratory tract infections; Melioidosis
  • Discontinued Bone and joint infections; Osteomyelitis; Skin and soft tissue infections

Most Recent Events

  • 10 Oct 2023 Arrevus in collaboration with Arnasi Group completes a phase II trial in Melioidosis (Combination therapy) in Thailand (PO) (NCT05105035)
  • 19 Jul 2023 Aceragen withdrawan a phase II trial due to financial issues associated respiratory tract infections (In adolescents, In adults, In the elderly) for Cystic fibrosis in USA (NCT05641298)
  • 13 Mar 2023 Aceragen has patent protection for fusidic acid in US, Japan and Canada prior to March 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top